These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein (IGFBP)-3 levels in Arab subjects with coronary heart disease. Akanji AO; Suresh CG; Al-Radwan R; Fatania HR Scand J Clin Lab Invest; 2007; 67(5):553-9. PubMed ID: 17763192 [TBL] [Abstract][Full Text] [Related]
44. Obesity, adipokines, and prostate cancer in a prospective population-based study. Baillargeon J; Platz EA; Rose DP; Pollock BH; Ankerst DP; Haffner S; Higgins B; Lokshin A; Troyer D; Hernandez J; Lynch S; Leach RJ; Thompson IM Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1331-5. PubMed ID: 16835332 [TBL] [Abstract][Full Text] [Related]
45. Insulin-like growth factor-II (IGF-II), IGF-binding protein-3 (IGFBP-3), and IGFBP-4 in follicular fluid are associated with oocyte maturation and embryo development. Wang TH; Chang CL; Wu HM; Chiu YM; Chen CK; Wang HS Fertil Steril; 2006 Nov; 86(5):1392-401. PubMed ID: 17070193 [TBL] [Abstract][Full Text] [Related]
46. Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Liao Y; Abel U; Grobholz R; Hermani A; Trojan L; Angel P; Mayer D Hum Pathol; 2005 Nov; 36(11):1186-96. PubMed ID: 16260272 [TBL] [Abstract][Full Text] [Related]
47. Transforming growth factor-beta1 modulates tumor-stromal cell interactions of prostate cancer through insulin-like growth factor-I. Kawada M; Inoue H; Arakawa M; Ikeda D Anticancer Res; 2008; 28(2A):721-30. PubMed ID: 18507013 [TBL] [Abstract][Full Text] [Related]
48. Insulin-like growth factors and subsequent risk of mortality in the United States. Saydah S; Graubard B; Ballard-Barbash R; Berrigan D Am J Epidemiol; 2007 Sep; 166(5):518-26. PubMed ID: 17602136 [TBL] [Abstract][Full Text] [Related]
49. Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. Wolpin BM; Michaud DS; Giovannucci EL; Schernhammer ES; Stampfer MJ; Manson JE; Cochrane BB; Rohan TE; Ma J; Pollak MN; Fuchs CS Br J Cancer; 2007 Jul; 97(1):98-104. PubMed ID: 17533398 [TBL] [Abstract][Full Text] [Related]
51. Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study. Lacey JV; Hsing AW; Fillmore CM; Hoffman S; Helzlsouer KJ; Comstock GW Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1101-2. PubMed ID: 11588138 [No Abstract] [Full Text] [Related]
52. Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies. Morris JK; George LM; Wu T; Wald NJ Br J Cancer; 2006 Jul; 95(1):112-7. PubMed ID: 16804529 [TBL] [Abstract][Full Text] [Related]
53. Serum enterolactone concentration is not associated with prostate cancer risk in a nested case-control study. Kilkkinen A; Virtamo J; Virtanen MJ; Adlercreutz H; Albanes D; Pietinen P Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1209-12. PubMed ID: 14652283 [TBL] [Abstract][Full Text] [Related]
54. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. Chan JM; Stampfer MJ; Ma J; Gann P; Gaziano JM; Pollak M; Giovannucci E J Natl Cancer Inst; 2002 Jul; 94(14):1099-106. PubMed ID: 12122101 [TBL] [Abstract][Full Text] [Related]
55. Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. Cao Y; Nimptsch K; Shui IM; Platz EA; Wu K; Pollak MN; Kenfield SA; Stampfer MJ; Giovannucci EL Int J Cancer; 2015 May; 136(10):2418-26. PubMed ID: 25348852 [TBL] [Abstract][Full Text] [Related]
56. IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Weiss JM; Huang WY; Rinaldi S; Fears TR; Chatterjee N; Chia D; Crawford ED; Kaaks R; Hayes RB Int J Cancer; 2007 Nov; 121(10):2267-73. PubMed ID: 17597108 [TBL] [Abstract][Full Text] [Related]
57. Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. Miles FL; Goodman PJ; Tangen C; Torkko KC; Schenk JM; Song X; Pollak M; Thompson IM; Neuhouser ML Nutrients; 2017 Apr; 9(4):. PubMed ID: 28417914 [TBL] [Abstract][Full Text] [Related]
58. Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death: a case-control study nested in the Japan Collaborative Cohort (JACC) Study. Wakai K; Ito Y; Suzuki K; Tamakoshi A; Seki N; Ando M; Ozasa K; Watanabe Y; Kondo T; Nishino Y; Ohno Y; Jpn J Cancer Res; 2002 Dec; 93(12):1279-86. PubMed ID: 12495466 [TBL] [Abstract][Full Text] [Related]
59. Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. Oliver SE; Gunnell D; Donovan J; Peters TJ; Persad R; Gillatt D; Pearce A; Neal DE; Hamdy FC; Holly J Int J Cancer; 2004 Mar; 108(6):887-92. PubMed ID: 14712493 [TBL] [Abstract][Full Text] [Related]
60. Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Wolpin BM; Michaud DS; Giovannucci EL; Schernhammer ES; Stampfer MJ; Manson JE; Cochrane BB; Rohan TE; Ma J; Pollak MN; Fuchs CS Cancer Res; 2007 Aug; 67(16):7923-8. PubMed ID: 17699799 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]